By using avasimibe, a potent inhibitor of ACAT-1, we found that pancreatic cancer cells MIA PaCa-2 and PANC-1 were much more sensitive to ACAT-1 inhibition than normal HPDE6 cells (Figure 4a, Supplementary Figure S4A). This evidence concerns the gene ACAT1 and pancreatic neoplasm.